Savitha Krishnan, MD
Urogynecology and Reconstructive Pelvic Surgery · Mountain View, CANPI 1447323092
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $188,313 of the $242,844 with a category attached, or 77.5%. 14 manufacturers reported payments, led by Medtronic at 43.3% of the total. 2025 is the largest year on record at $79,221, 8.4 times the $9,461 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $647.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$105K
- Boston Scientific$61K
- AbbVie$31K
- Sumitomo Pharma America, Inc.$27K
- Intuitive Surgical$12K
- Axonics, Inc.$3K
- plus $4K from 8 others
Across 1 payment — averaging $315.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$315
What the payments were for
- Consulting fees$14,5306%
- Speaking & faculty fees$188,31378%
- Travel & lodging$26,24711%
- Food & beverage$9,5454%
- Education$4,1802%
- Gifts$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 166 | $105,192 |
| Boston Scientific | 75 | $60,874 |
| AbbVie(2 entities) | 41 | $30,649 |
| Sumitomo Pharma America, Inc. | 25 | $27,243 |
| Intuitive Surgical | 22 | $12,117 |
| Axonics, Inc. | 19 | $2,574 |
| Valencia Technologies Corporation | 4 | $1,515 |
| Coloplast | 12 | $1,432 |
| Applied Medical Resources Corporation | 3 | $506 |
| Caldera Medical, Inc | 3 | $471 |
| Astellas Pharma US Inc | 2 | $180 |
| Stryker | 1 | $42 |
| Bluewind Medical | 1 | $31 |
| Rochester Medical Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$81,702
- BOTOX$29,725
- GEMTESA$26,927
- UPSYLON$18,856
- Advantage System$18,428
- Da Vinci Surgical System$11,491
- GENERAL FEMALE SUI$6,588
- UROMAX ULTRA$4,125
- GENERAL - THERAPIES$4,080
- COLPASSIST$2,520
- ADVANTAGE$2,188
- Axonics$2,053
- eCoin Device Kit$1,479
- ALTIS$1,129
- ALTAVIVA$693
- DA VINCI SP$500
- GelPOINT V-Path$465
- AMS 800 Artificial Urinary Sphincter$425
- Desara$355
- Axonics r-SNM System$221
How this compares
$242,844 in reported general payments places this provider in the 95th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 248 | $277,426 |
| MyrbetriqMirabegron | 83 | $62,468 |
| PremarinEstrogens, Conjugated | 120 | $51,450 |
| EstringEstradiol | 26 | $13,391 |
| Estradiol | 184 | $11,729 |
| YuvafemEstradiol | 11 | $2,138 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 231 | $1,740 |
| Methenamine Hippurate | 23 | $1,195 |
| Ibuprofen | 70 | $509 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 68 | $446 |
| Cephalexin | 64 | $301 |
| Desmopressin Acetate | 11 | $237 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 70 | $153 |
| Ciprofloxacin Hcl | 28 | $115 |
| Fluconazole | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $27,243 | $277,426248 claims |
| Astellas Pharma US IncMyrbetriq | $180 | $62,46883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Mountain View
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
- Seshadri KasturiSacramento$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.